1. Introduction {#sec1}
===============

Sepsis is a clinical entity involving a massive systemic inflammatory response, which may result in septic shock, multiple organ system failure, and death \[[@B1]\]. Although the methods of treatment are constantly updated and refined, sepsis and septic shock remain the most prevalent causes of death in intensive care units (ICUs). Recently, peroxisome proliferator-activated receptor gamma (PPAR-*γ*) was described as playing a role in modulating the pathological status of sepsis by regulating energy metabolism, inflammation, and immune cell function \[[@B2]\].

PPAR-*γ*, a member of the nuclear hormone receptor superfamily, is a ligand-binding nuclear receptor whose activation controls the inflammatory response \[[@B3]\]. PPAR-*γ* has been shown to regulate inflammatory status by controlling the differentiation of monocytes and macrophages and by suppressing the expression of inflammatory cytokines, such as tumor necrosis factor alpha (TNF-*α*), interleukin-1 beta (IL-1*β*), inducible cyclooxygenase-2 (COX-2), and other downstream markers of inflammation \[[@B3]--[@B5]\]. In animal models of sepsis and septic shock, PPAR-*γ* agonist pretreatment markedly attenuated inflammation compared with controls \[[@B6], [@B7]\]. Therefore, PPAR-*γ* has been suggested to be beneficial in sepsis. However, PPAR-*γ* induces apoptosis, and the death of immune cells, especially T lymphocytes, is generally considered deleterious \[[@B2]\]. Under these circumstances, a second infection cannot be adequately cleared, leading to septic shock and multiple organ dysfunction syndrome. Because of the profound involvement of PPAR-*γ* in sepsis, we explored the possibility of PPAR-*γ* as a candidate gene for sepsis susceptibility.

The most common functional polymorphism in the*PPAR*-*γ* gene is a CCA-to-GCA missense mutation (rs1801282) in codon 12 of exon B, which results in the replacement of proline 12 with alanine (Pro12Ala) \[[@B8]\] and a reduction in the transcriptional activity of PPAR-*γ* \[[@B9]\]. Previous studies have examined the PPAR-*γ* Pro12Ala polymorphism in a variety of inflammatory diseases, such as atherosclerosis, psoriatic arthritis, inflammatory bowel disease, and multiple sclerosis \[[@B10]--[@B13]\], but none have documented an association between this polymorphism and sepsis. Therefore, we conducted a hospital-based case-control study to investigate whether this functional polymorphism of the*PPAR*-*γ* gene affects the risk, disease severity, and outcome of sepsis in a Chinese Han population.

2. Materials and Methods {#sec2}
========================

2.1. Participant Recruitment {#sec2.1}
----------------------------

In this study, all the subjects were recruited from the Department of Emergency and ICU of the Affiliated Hospital of Guangdong Medical College between March 2011 and October 2013. Blood samples were collected from the subjects upon the diagnosis of sepsis, severe sepsis, or septic shock. These patients were diagnosed with sepsis, severe sepsis, or septic shock according to the 1991 ACCP/SCCM Joint Meeting \[[@B14]\] and the diagnostic criteria developed at the 2001 International Sepsis Definition Conference \[[@B15]\]. Patients below 18 years of age or suffering from diabetes, immunological diseases, or malignancies were excluded from this study. A total of 308 patients with sepsis were observed during the ICU stay until death or hospital discharge occurred. The Acute Physiology and Chronic Health Evaluation II (APACHE-II) and Sequential Organ Failure Assessment (SOFA) scores were determined on the day of ICU admission and were used to evaluate illness severity and organ dysfunction/failure, respectively. Based on 28-day survival data, the patients with sepsis were further divided into a survivor group (≥28-day survival) and a nonsurvivor group (\<28-day survival). All the patients were observed for 28-day survival, which was calculated from the date of the primary diagnosis of sepsis. Upon admission to the ICU, patients with sepsis underwent the daily collection of physiologic and laboratory data, for example, gender, age, chronic disease status, cause of sepsis, site of infection, chief complications, duration of ICU stay, duration of hospital stay, prognosis, APACHE-II scores, and SOFA scores. Concurrently, 345 healthy Chinese Han individuals were genotyped and functioned as a control population for the genotype analysis. The Ethics Committee of the Affiliated Hospital of Guangdong Medical College approved this study, and informed consent was obtained from the patients and/or their family members.

2.2. DNA Extraction and Genotyping {#sec2.2}
----------------------------------

Genomic DNA was isolated from the EDTA blood samples collected from all of the patients and controls using the Blood DNA Kit (Tiangen Biotech, Beijing, China) according to the manufacturer\'s instructions. For each sample, the PPAR-*γ* Pro12Ala genotype was determined using the polymerase chain reaction-ligation detection reaction (PCR-LDR) method. The PCR primers for Pro12Ala were as follows: forward primer 5′-TGATGTCTTGACTCATGGGTGT-3′ and reverse primer 5′-TACATAAATGCCCCCACGTC-3′. PCR was performed in a Perkin-Elmer GeneAmp PCR System 9600 (Applied Biosystems, USA) in a total reaction volume of 20 *μ*L containing 1 *μ*L of genomic DNA, 2 *μ*L of 1× Taq buffer, 0.4 *μ*L of each primer, 2 *μ*L of dNTPs, 0.3 *μ*L of Qiagen HotStarTaq polymerase (Qiagen, Germany), and 9.8 *μ*L of H~2~O. The amplification parameters were as follows: denaturation at 95°C for 15 min; 35 cycles of denaturation at 94°C for 30 s, annealing at 57°C for 90 s and extension at 72°C for 60 s; and a final extension step at 72°C for 10 min. The probes for LDR were as follows: 5′-P-GTCAATAGGAGAATCTCCCAGAGT -FAM-3′, with a phosphorylated 5′ end and a 6-carboxyXuorescein (FAM)-labeled 3′ end; a C-specific probe, 5′-TGTATCAGTGAAGGAATCGCTTTCTGG-3′; and a G-specific probe, 5′-TTTGTATCAGTGAAGGAATCGCTTTCTGC-3′. A ligation reaction was performed with each PCR product; the final volume of 10 *μ*L contained 2 *μ*L of PCR product, 1 *μ*L of 1× Taq DNA ligase buffer, 1 *μ*L of probe mixture, 2 U of Taq DNA ligase (New England Biolabs, USA), and 6.95 *μ*L of H~2~O. The reaction conditions for LDR were as follows: denaturation at 95°C for 2 min, followed by 30 cycles of 94°C for 15 s and 50°C for 25 s. The fluorescent LDR products were analyzed using an ABI 377 DNA Sequencer (Applied Biosystems, USA).

2.3. Statistical Analysis {#sec2.3}
-------------------------

The statistical analysis was performed with SPSS version 19.0 (SPSS Inc., Chicago, IL, USA). The results for continuous variables with normal distributions are provided as means ± standard deviations (SD). Student\'s *t*-test was performed to compare means between two groups. The genotype distributions of all the groups were assessed for deviations from Hardy-Weinberg equilibrium. Allele and genotype frequencies were compared using the chi-squared test or Fisher\'s exact two-tailed tests when appropriate. Kaplan-Meier survival analysis in 28 days was used to explore the mortality differences. The log-rank test was used to evaluate the univariate relationship between the PPAR-*γ* Pro12Ala genotype and clinical outcome. Values of *P* \< 0.05 were considered statistically significant.

3. Results {#sec3}
==========

3.1. Clinical Characteristics {#sec3.1}
-----------------------------

The baseline characteristics and clinical data of all the subjects are shown in [Table 1](#tab1){ref-type="table"}. The average age and sex distribution did not differ significantly between the sepsis and healthy control groups or between the survivor and nonsurvivor groups. The respiratory tract (77.9%), bloodstream (27.6%), and abdomen (35.4%) were the main sites of infection. Gram-negative infections (33.8%) and mixed infections (35.1%) were the primary infection types, while fungal infections accounted for 10.4%. Among the total group of sepsis patients, 45.8% exhibited three or more organ dysfunctions. Severe sepsis accounted for 58.8% of the sepsis patients. The overall 28-day mortality rate of the sepsis patients was 36.5%.

3.2. Distributions of Genotypes and Allele Frequencies in Sepsis Patients and Controls {#sec3.2}
--------------------------------------------------------------------------------------

A total of 308 sepsis patients and 345 healthy control subjects were successfully analyzed for the Pro12Ala polymorphism. The genotype and allele frequency distributions of this single-nucleotide polymorphism (SNP) in the patient groups and control groups in our cohort are presented in [Table 2](#tab2){ref-type="table"}. The allele and genotype distributions for the assayed locus, rs1801282, of the patients with sepsis and controls indicated that both groups were in Hardy-Weinberg equilibrium (*P* = 0.536 and 0.449, resp.). The frequencies of the Pro12Pro and Pro12Ala genotypes were 93.18% and 6.82%, respectively, in the case group, and 92.17% and 7.83%, respectively, in the control group. None of the individuals in our study cohort had the Ala12Ala genotype.

3.3. Disease Severity and Genotype {#sec3.3}
----------------------------------

We divided the sepsis cases into three subtypes (sepsis, septic shock, and severe sepsis) and investigated the association between the SNP and each subtype. As shown in [Table 3](#tab3){ref-type="table"}, there were significant differences in the genotype distribution and allele frequency between the sepsis subtype and the healthy controls. The frequency of the Ala allele in the sepsis subtype was significantly higher than in the healthy controls (*P* = 0.014, odds ratio (OR) = 3.243, and 95% confidence interval (CI) (1.349--7.796) for allele and *P* = 0.012, OR = 3.585, and 95% CI (1.410--9.111) for genotype). Furthermore, after Benjamini-Hochberg (BH) multiple testing correction was performed, the difference remained significant (*P*\* (corr) = 0.042 for genotype and *P*\* (corr) = 0.042 for allele). There were no significant differences in genotype distribution or allele frequency between the healthy controls and the septic shock or severe sepsis subtype.

We also separated the sepsis cases into two groups, survivors and nonsurvivors, on the basis of the patients\' 28-day mortality. Only one patient in the nonsurvivor group had the Pro12Ala genotype. Significant differences in genotype and allele frequencies were found between the survivors and nonsurvivors in the overall group of sepsis patients (*P* = 0.002, *P*\* (corr) = 0.002 for genotype and *P* = 0.002, *P*\* (corr) = 0.002 for allele) ([Table 4](#tab4){ref-type="table"}).

3.4. Mortality and Genotype {#sec3.4}
---------------------------

A total of 112 (36.5%) patients died during hospitalization. The mortality increased with increasing severity of the disease, from 13.3% for sepsis to 32.0% and 51.5% for severe sepsis and septic shock, respectively (*P* \< 0.001). The overall group of patients with sepsis (308 cases) was further divided into two groups according to genotype.

Based on a log-rank test for trend, the Ala12 allele carriers had significantly increased 28-day survival compared with the Pro12 carriers (*P* = 0.004) ([Figure 1(a)](#fig1){ref-type="fig"}). However, stratification by subtypes (sepsis subtype, severe sepsis, and septic shock) did not reveal a statistical difference between the Pro12 and the Ala12 allele carriers in sepsis patients (Figures [1(b)](#fig1){ref-type="fig"}, [1(c)](#fig1){ref-type="fig"}, and [1(d)](#fig1){ref-type="fig"}). A small trend, although not significant, was observed between the Pro12 and the Ala12 allele carriers in septic shock patients (*P* = 0.078) ([Figure 1(d)](#fig1){ref-type="fig"}).

3.5. Association Analysis of the PPAR-*γ* Gene Polymorphism and Sepsis Outcome in Survivors {#sec3.5}
-------------------------------------------------------------------------------------------

The patients in the survivor group were divided into two groups according to their genotype. There were significant differences between the two groups in the APACHE-II score, SOFA score, duration of ICU stay, and duration of hospital stay. The patients with the Pro12Pro genotype had worse disease severity and increased recovery time compared with the patients with the Pro12Ala genotype ([Table 5](#tab5){ref-type="table"}).

4. Discussion {#sec4}
=============

We investigated a common SNP, Pro12Ala, in the PPAR-*γ* gene in 308 patients with clinically defined sepsis and 345 age-matched healthy controls, and we evaluated the effects of this SNP on disease risk and progression. No significant differences were found in the genotype distribution and allele frequency of the PPAR-*γ* Pro12Ala polymorphism between the sepsis patients and healthy controls. However, in the group of survivors, we found that carrying the Ala allele of the Pro12Ala polymorphism was significantly associated with disease severity. Based on our Kaplan-Meier survival analysis, 28-day survival was significantly reduced in individuals with the Pro12Pro genotype compared with the Pro12Ala genotype. The Ala12 carriers had lower disease severity scores, lower mortality, and faster recovery compared with the patients with wild-type genotypes. Our population-based study demonstrated that the Pro12Ala polymorphism allele might not serve as a marker for susceptibility to sepsis but could influence a patient\'s clinical outcome and risk of dying from sepsis.

PPAR-*γ* is a nuclear receptor expressed in monocytes, macrophages, T cells, endothelial cells, and other cells involved in the progression of sepsis \[[@B4], [@B16]--[@B19]\]. Importantly, compared with control subjects, increases in PPAR-*γ* expression and activity have been reported in T lymphocytes and polymorphonuclear neutrophils isolated from either mice or human patients with sepsis \[[@B16], [@B20], [@B21]\]. PPAR-*γ* activation during the onset of sepsis inhibits inflammatory gene expression and can negatively interfere with proinflammatory transcription factor signaling pathways in inflammatory cells, resulting in the prevention of sepsis progression via an attenuation of the hyperinflammatory response. The body diminishes the harmful effects of the late phase of sepsis by producing anti-inflammatory cytokines and enhancing immune paralysis via immune cell apoptosis \[[@B22], [@B23]\]. Hotchkiss and colleagues showed that the depletion of lymphocytes is the central pathogenic event during sepsis and is a major contributor to poor outcomes following sepsis \[[@B22], [@B24]--[@B27]\]. Compared with the major (Pro) allele, the minor (Ala) allele of PPAR-*γ* is less biochemically active; therefore, we speculated that the improved survival and outcome of Ala carriers might be due to an attenuation of T cell apoptosis. Our results provide strong support for this hypothesis. In addition, the survival advantage conferred by the Ala12 allele during sepsis is also supported by*in vivo* studies of T cell-specific PPAR-*γ* knockout mice and*in vitro* studies of PPAR-*γ* inhibition in T cells using the PPAR-*γ* antagonist GW9662 \[[@B16]\].

To our knowledge, our study is the first to analyze the association between the PPAR-*γ* Pro12Ala polymorphism and sepsis in a Chinese Han population. In this study, the Ala allele of the PPAR-*γ* Pro12Ala polymorphism was associated with significant benefits in the clinical outcome of sepsis. Previous studies have reported that the Ala allele was correlated with lower PPAR-*γ* transcriptional activity and have characterized the PPAR-*γ* Pro12Ala polymorphism in a variety of inflammatory diseases, such as type 2 diabetes mellitus, atherosclerosis, ulcerative colitis, Crohn\'s disease, psoriatic arthritis, and diabetic nephropathy \[[@B10]--[@B12], [@B28], [@B29]\]. Most of these studies observed a protective effect in carriers of the Ala allele. Although the present study found no significant differences between the healthy controls and sepsis patients in the distribution of Pro12Ala genotypes or alleles, the sepsis patients in the survivor with the PPAR-*γ* Pro12Ala genotype had milder disease and faster recovery than those with the Pro12Pro genotype.

The Ala12 allele frequency of the Pro12Ala SNP varies widely among continental and ethnic groups; reported Ala12 allele frequencies include 0.15 in a Finnish population, 0.12 in a German population, 0.082 in an Italian population, and 0.034 in a Chinese population \[[@B30]\]. In the context of sepsis, this variation might result in diverse genetic roles of this polymorphism in different populations. Therefore, it will be necessary to confirm our findings in patients of different ethnicities.

In summary, our results reveal that the PPAR-*γ* Pro12Ala polymorphism is not associated with sepsis in the studied Chinese Han population, but the observed genetic difference may be important in influencing clinical outcome.

Support for this work includes funding from the National Nature Science Foundation of China (Grant nos. 31171219, 81261120404, 81271213, 81270196, and 81271214), Science and Technology Planning Project of Guangdong Province (no. 2011B03180023), the Science and Technology Innovation Fund of Guangdong Medical College (no. STIF 201101), and Doctor Startup Fund of Guangdong Medical College (no. XB1326).

Conflict of Interests
=====================

The authors declare that there is no conflict of interests regarding the publication of this paper.

Authors\' Contribution
======================

Guoda Ma, Haiyang Wang, and Guixi Mo contributed equally to this work.

![28-day survival rates of patients with sepsis. Kaplan-Meier estimates were used to calculate the probability of 28-day survival according to the PPAR-*γ* Pro12Ala genotype. The carriers of the Pro12Pro genotype had significantly decreased 28-day survival compared with the carriers of the Pro12Ala genotype. (a) Pro12Pro carriers versus Pro12Ala carriers; (b) Pro12Pro carriers versus Pro12Ala carriers in Sepsis subtype subgroup; (c) Pro12Pro carriers versus Pro12Ala carriers in severe sepsis subgroup; (d) Pro12Pro carriers versus Pro12Ala carriers in severe sepsis subgroup in septic shock subgroup.](PPAR2014-701971.001){#fig1}

###### 

Demographic and clinical characteristics of the study subjects in the sepsis and control groups.

  Characteristics                                Cases (*n* = 308)   Controls (*n* = 345)   *P* value
  ---------------------------------------------- ------------------- ---------------------- -----------
  Age (years)                                    62.36 ± 17.17       54.90 ± 15.73          0.412
  Male/female, *n*                               217/91              222/123                0.097
                                                                                            
  Organ dysfunction                                                                         
  One, *n* (%)                                   48 (15.6)           N.A.                    
  Two, *n* (%)                                   89 (28.9)           N.A.                    
  Three or more, *n* (%)                         141 (45.8)          N.A.                    
                                                                                            
  Sepsis status                                                                             
  Sepsis, *n* (%)                                30 (9.7)            N.A.                    
  Septic shock, *n* (%)                          97 (31.5)           N.A.                    
  Severe sepsis, *n* (%)                         181 (58.8)          N.A.                    
                                                                                            
  Source of infection, *n* (%)                                                              
  Respiratory tract infection                    240 (77.9)          N.A.                    
  Primary bloodstream infection                  85 (27.6)           N.A.                    
  Wound infection                                38 (12.3)           N.A.                    
  Abdominal infection                            109 (35.4)          N.A.                    
  Urinary tract infection                        13 (4.2)            N.A.                    
  Catheter-associated infection                  25 (8.1)            N.A.                    
  Other                                          19 (6.2)            N.A.                    
                                                                                            
  Pathogens, *n* (%) (positive blood cultures)                                              
  Gram-negative                                  104 (33.8)          N.A.                    
  Gram-positive                                  51 (16.5)           N.A.                    
  Mixed Gram-negative and positive               108 (35.1)          N.A.                    
  Fungus                                         32 (10.4)           N.A.                    
  Negative blood cultures                        13 (4.2)            N.A.                    
  APACHE-II score                                23.1 ± 4.7          N.A.                    
  28-day mortality, *n* (%)                      36.5                N.A.                    

N.A.: not Applicable; APACHE II: Acute Physiology and Chronic Health Evaluation II.

###### 

Distributions of genotypes and allele frequencies in controls and patients with sepsis.

  ----------------------------------------------------------------------------------------------
  Genotype   All sepsis cases, \   Controls, \   *P* value   *P* value∗   OR (95% CI)
             *n* (%)               *n* (%)                                
  ---------- --------------------- ------------- ----------- ------------ ----------------------
  Total      308                   345           0.622       0.629        1.160 (0.642--2.098)

  Pro12Pro   287 (93.18)           318 (92.17)                             

  Pro12Ala   21 (6.82)             27 (7.83)                               

  Ala12Ala   0 (0)                 0 (0)                                   

  Allele                                                                   

   Pro       595 (96.59)           663 (96.09)   0.629       0.629        1.154 (0.645--2.063)

   Ala       21 (3.41)             27 (3.91)                               
  ----------------------------------------------------------------------------------------------

OR: odds ratio; 95% CI: 95% confidence interval. \*False discovery rate adjusted  *P* value for multiple hypothesis testing using the Benjamini-Hochberg method.

###### 

Distributions of genotype and allele frequencies in the sepsis subtypes and healthy controls.

  --------------------------------------------------------------------------------------------------------------------------------------------
  Genotype   Healthy controls\   Sepsis (subtype)\   Septic shock\   Severe sepsis\   *P* value   *P* value∗                           
             *n* (%)             *n* (%)             *n* (%)         *n* (%)                                                           
  ---------- ------------------- ------------------- --------------- ---------------- ----------- ------------ ------- ------- ------- -------
  Total      345                 30                  97              181              0.012       0.264        0.327   0.042   0.336   0.336

  Pro12Pro   318 (92.17)         23 (76.67)          93 (95.88)      171 (94.48)                                                        

  Pro12Ala   27 (7.83)           7 (23.33)           4 (4.12)        10 (5.52)                                                          

  Allele                                                                                                                                

   Pro       663 (96.09)         53 (88.33)          190 (97.94)     352 (97.24)      0.014       0.273        0.336   0.042   0.336   0.336

   Ala       27 (3.91)           7 (11.67)           4 (2.06)        10 (2.76)                                                          
  --------------------------------------------------------------------------------------------------------------------------------------------

OR: odds ratio; 95% CI: 95% confidence interval. \*False discovery rate adjusted  *P* value for multiple hypothesis testing using the Benjamini-Hochberg method. *P*1 and *P*1\*: healthy control group versus sepsis group. *P*2 and *P*2\*: healthy control group versus septic shock group. *P*3 and *P*3\*: healthy control group versus severe sepsis group. Fisher\'s exact test: *P*1 = 0.012, OR = 3.585, and 95% CI (1.410--9.111) for genotype and *P*1 = 0.014, OR = 3.243, 95% CI (1.349--7.796) for allele.

###### 

Distributions of genotype and allele frequencies among surviving and nonsurviving patients.

  -----------------------------------------------------------------------------------------
  Genotype   Survivors\    Nonsurvivors\   *P* value   *P* value∗   OR (95% CI)
             *n* (%)       *n* (%)                                  
  ---------- ------------- --------------- ----------- ------------ -----------------------
  Total      196           112                                       

  Pro12Pro   176 (89.80)   111 (99.11)     0.002       0.002        12.614 (1.669--95.31)

  Pro12Ala   20 (10.20)    1 (0.09)                                  

  Allele                                                             

   Pro       372 (94.90)   223 (99.55)     0.002       0.002        11.989 (1.598--89.95)

   Ala       20 (5.10)     1 (0.45)                                  
  -----------------------------------------------------------------------------------------

OR: odds ratio; 95% CI: 95% confidence interval. \*False discovery rate adjusted  *P* value for multiple hypothesis testing using the Benjamini-Hochberg method.

###### 

Association between genotype and sepsis outcome in the survivor group.

  Genotype     *n*   APACHE-II score   SOFA score    ICU stay (days)   Hospital stay (days)
  ------------ ----- ----------------- ------------- ----------------- ----------------------
  Pro12Pro     176   20.78 ± 3.7       11.21 ± 4.2   18.75 ± 3.9       25.981 ± 7.1
  Pro12Ala     20    15.01 ± 3.3       7.05 ± 2.8    12.33 ± 2.4       17.72 ± 5.1
  *P* value          0.031             0.029         0.025             0.021
  *P* value∗         0.031             0.031         0.031             0.031

\*False discovery rate adjusted  *P* value for multiple hypothesis testing using the Benjamini-Hochberg method.
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